Investitionsthese
Newton Biocapital invests in life-sciences innovation and supports portfolio companies to create value for patients, society, local ecosystems, and investors, drawing on connections between Europe and Japan.
Investitionsphase
Mature innovation and growth-stage companies
Bevorzugte Reifephase für die erste Finanzierung.
Sektoren & Themen
Life sciences and solutions for chronic health conditions
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Ticketgröße
€60.275.000 - €77.775.000
Standard-Finanzierungsbetrag pro Runde.
Outreach & Dossier-Analysen
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
Investment Team (16)
A
Ajit Shetty
Chairman of the Board of NBC I and NBC II
A
Alain Parthoens
Chief Executive Officer, Founder
D
Daisuke Morishita
Venture Partner
D
Danny Gonnissen
Chief Operating Officer
D
Dario Padovani
Chief Financial Officer
D
Dirk Boogmans
Vice-Chairman and Chairman of the Audit Committee of NBC I and NBC II
E
Els Hubloux
Partner
G
Goro Takeda
Founder
G
Guy Heynen
Chief Medical and Regulatory Officer
J
Jean Combalbert
Independent Director
J
Jean-Claude Deschamps
Chairman Emeritus and Advisor to the Board of NBC I and NBC II
M
Michihiko Wada
Chief Regulatory and Development Officer
P
Philippe De Backer
Senior Partner
P
Pierre Detrixhe
Venture Director
S
Sadashi Suzuki
Japan Representative
T
Tomoko Asaoka
Scientific Director